- Acorda Therapeutics (NASDAQ:ACOR) is down another 4.2% postmarket after holders filed to offer up to 9.599M shares of common stock.
- More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET. To participate in the webcast, please use the following registration link: http...
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...